Watson Pharmaceuticals Inc.,; Actavis Inc.,; Actavis Pharma Holding 4 Ehf.,; Actavis S.Á.R.L.
Volume 166 · 166 F.T.C. 572
Cite this decision
Watson Pharmaceuticals Inc.,; Actavis Inc.,; Actavis Pharma Holding 4 Ehf.,; Actavis S.Á.R.L., 166 F.T.C. 572 (2018). Consumer Law Library, https://consumerlawlibrary.org/decisions/v166-0028
Report an error in this record (decision id v166-0028)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MATTER OF WATSON PHARMACEUTICALS INC., ACTAVIS INC., ACTAVIS PHARMA HOLDING 4 EHF., AND ACTAVIS S.Á.R.L.
Docket No. C-4373. Order, December 17, 2018 Letter Order approving the Fourth Amendment to the Development and Manufacturing Services Agreement. LETTER ORDER APPROVING AMENDMENT Maria A. Raptis, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP Re: In the Matter of Watson Pharmaceuticals Inc., et al., Docket No. C-4373 Dear Ms. Raptis:
This letter responds to the Petition of Respondent Teva Pharmaceutical Industries Ltd. to Reopen and Modify Decision and Order (“Petition”) filed on October 22, 2018. The Petition was placed on the public record for comments until November 23, 2018, and no comments were received. In its Order Reopening and Modifying Order, issued on December 17, 2018, the Commission reopened and modified the Decision and Order as requested in the Petition. The Commission also approved the Proposed Fourth Amendment to the Development and Manufacturing Services Agreement as requested in the Petition. In according its approval, the Commission has relied upon the information submitted and the representations made in the Petition and has assumed them to be accurate and complete. By direction of the Commission, Commissioner Wilson recused. 573 1-800 CONTACTS, INC. Interlocutory Orders, Etc.